Insta
Serum Institute of India (Pic Via Twitter)
In a positive development in the nation's fight to put an end tp the COVID-19 pandemic's spread, Pune based Serum Institute of India (SII)'s chief executive Adar Poonawalla has said that the company will give India priority for the delivery of the Covidshield vaccine developed by pharmaceutical major and AstraZeneca and the University of Oxford, reports Livemint.
Poonawalla also shared that he expected about 90 per cent of all the doses produced by it to be sold to the Government of India for around Rs 250 per piece (about $3). Meanwhile, the remaining ten per cent of the vaccines may be sold in the private market at a higher price of Rs 1,000.
Poonawalla also shared that the company is hoping for the emergency use license to roll out some doses of Covidshield by the end of December or January.
Meanwhile, it should also be noted that Prime Minister (PM) Narendra Modi is expected to hold a meeting with State leaders on today (24 November) to discuss the distribution of the vaccine.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.
Latest